Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

被引：8

作者：

Shah, Nina ^{[1
]}

Munshi, Nikhil C. ^{[2
]}

Berdeja, Jesus G. ^{[3
,4
]}

Jagannath, Sundar ^{[5
]}

Finney, Olivia ^{[6
]}

Martin, Nathan ^{[7
]}

Agarwal, Amit ^{[7
]}

Rowe, Everton ^{[7
]}

Campbe, Timothy B. ^{[7
]}

San-Miguel, Jesus F. ^{[8
]}

机构：

[1] UCSF, Med Ctr, San Francisco, CA USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[3] Tennessee Oncol, Nashville, TN USA

[4] Sarah Cannon Canc Ctr, Nashville, TN USA

[5] Mt Sinai Med Ctr, New York, NY USA

[6] Bluebird bio, Cambridge, MA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-148375

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1739

引用

页数：5

共 50 条

[1] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
Cavo, M.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I.
Delforge, M.
Einsele, H.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J.
Patel, P.
Huang, L.
Campbell, T.
Hege, K.
Munshi, N.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
[2] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
Anderson, Larry D., Jr.
Munshi, Nikhil C.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur S.
Siegel, David Samuel DiCapua
Lin, Yi
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Petrocca, Fabio
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
Einsele, H.
Weisel, K.
Goldschmidt, H.
Munshi, N. C.
Anderson, L. D., Jr.
Shah, N.
Jagannath, S.
Berdeja, J.
Lonial, S.
Raje, N.
Siegel, D. S.
Lin, Y.
Oriol, A.
Moreau, P.
Yakoub-Agha, I
Delforge, M.
Petrocca, F.
Connarn, J. N.
Patel, P.
Huang, L.
Campbell, T. B.
Hege, K.
San Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
[4] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
Einsele, H.
Oriol, A.
San-Miguel, J.
Kansagra, A.
Madduri, D.
Shah, N.
Moreau, P.
Yakoub-Agha, I
Delforge, M.
Cavo, M.
Goldschmidt, H.
Weisel, K.
Rambaldi, A.
Reece, D.
Rodriguez-Otero, P.
Petrocca, F.
Connarn, J. N.
Patel, P.
Huang, L.
Campbell, T. B.
Hege, K.
Munshi, N. C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
[5] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Einsele, Hermann
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
Munshi, Nikhil C.
Oriol, Albert
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
[6] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna E.
Rambaldi, Alessandro
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S18
[7] Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial
Weisel, K.
Einsele, H.
Goldschmidt, H.
Delforge, M.
San Miguel, J.
Bertin, K. B.
Tahir, M.
Lewis, H.
Wang, J.
Braverman, J.
Campbell, T. B.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 93 - 94
[8] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
Einsele, H.
Shah, N.
Munshi, N.
Berdeja, J.
Jagannath, S.
Finney, O.
Martin, N.
Agarwal, A.
Rowe, E.
Campbell, T. B.
San-Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
[9] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Delforge, Michel
Baz, Rachid C.
Cavo, Michele
Callander, Natalie S.
Ghobadi, Armin
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Massaro, Monica
Ding, Li
Patel, Payal
Pittari, Gianfranco
Novick, Steven
Giralt, Sergio A.
Berdeja, Jesus G.
BLOOD, 2020, 136
[10] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
Braverman, J.
Dhanda, D. S.
Moshkovich, O.
Lanar, S.
Miera, M.
Williams, A. E.
Murphy, R.
Devlen, J.
Hege, K.
Campbell, T. B.
VALUE IN HEALTH, 2021, 24 : S61 - S61

← 1 2 3 4 5 →